Edition:
United States

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

4.71USD
20 Apr 2018
Change (% chg)

$0.16 (+3.52%)
Prev Close
$4.55
Open
$4.54
Day's High
$4.85
Day's Low
$4.53
Volume
120,599
Avg. Vol
246,717
52-wk High
$7.34
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Viking Therapeutics - Pricing Public Offering Of 11 Mln Shares At $5 Per Share
Friday, 2 Feb 2018 08:33am EST 

Feb 2 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PRICING OF $55.0 MILLION PUBLIC OFFERING OF COMMON STOCK.VIKING THERAPEUTICS INC - PRICING OF ITS PUBLIC OFFERING OF 11 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $5.00 PER SHARE.  Full Article

Viking Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 1 Feb 2018 04:01pm EST 

Feb 1 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.VIKING THERAPEUTICS - INTENDS TO OFFER AND SELL, SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.VIKING THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED DEVELOPMENT OF ITS VK5211, VK2809 AND VK0214 PROGRAMS.  Full Article

Viking Therapeutics says Resale By Selling Stockholders Of Up To 2.6 Mln Shares
Wednesday, 20 Dec 2017 05:35pm EST 

Dec 20 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS - RESALE BY SELLING STOCKHOLDERS OF UP TO 2.6 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Sphera Funds Management Ltd Reports 7.43 Pct Passive Stake In Viking Therapeutics
Monday, 18 Dec 2017 09:59am EST 

Dec 18 (Reuters) - Viking Therapeutics Inc ::SPHERA FUNDS MANAGEMENT LTD REPORTS 7.43 PERCENT PASSIVE STAKE IN VIKING THERAPEUTICS INC AS OF DECEMBER 7 - SEC FILING.  Full Article

Viking Therapeutics Announces Closing Of Public Offering
Monday, 11 Dec 2017 04:15pm EST 

Dec 11 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK.  Full Article

Viking Therapeutics Announces Pricing Of $12.8 Million Public Offering Of Common Stock
Wednesday, 6 Dec 2017 08:09pm EST 

Dec 6 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PRICING OF $12.8 MILLION PUBLIC OFFERING OF COMMON STOCK.VIKING THERAPEUTICS INC- ‍ANNOUNCED PRICING OF ITS PUBLIC OFFERING OF 5,130,435 SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $2.50 PER SHARE​.  Full Article

Viking Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 5 Dec 2017 04:18pm EST 

Dec 5 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.VIKING THERAPEUTICS - INTENDS TO USE NET PROCEEDS FROM STOCK OFFERING FOR CONTINUED DEVELOPMENT OF ITS VK5211, VK2809 AND VK0214 PROGRAMS.  Full Article

Viking Therapeutics reports third quarter 2017 financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Viking Therapeutics Inc :Viking Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.22.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Viking Therapeutics files for sale of up to 6.9 mln shares by selling stockholder
Tuesday, 17 Oct 2017 05:09pm EDT 

Oct 17 (Reuters) - Viking Therapeutics Inc :Viking Therapeutics Inc files for sale of up to 6.9 million shares of co's common stock by selling stockholder Lincoln Park Capital Fund Llc‍‍​ - SEC filing.  Full Article

VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL
Friday, 29 Sep 2017 07:05am EDT 

Sept 29 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL.VIKING THERAPEUTICS INC - ‍ANNOUNCED IT HAS ENTERED INTO A $15.0 MILLION COMMON STOCK PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL FUND LLC​.VIKING THERAPEUTICS INC - CONTINUE TO ANTICIPATE TOP LINE RESULTS FROM PHASE 2 TRIAL OF VK5211 IN HIP FRACTURE IN Q4 OF 2017.VIKING THERAPEUTICS - CO WILL HAVE RIGHT AND SOLE DISCRETION TO SELL TO LPC UP TO $15 MILLION IN SHARES OF COMMON STOCK OVER 30-MONTH PERIOD CONTINGENT.VIKING THERAPEUTICS - ‍UNDER SEPARATE PURCHASE AGREEMENT, LINCOLN PARK CAPITAL FUND AGREED TO BUY $1.25 MILLION OF CO'S STOCK AT $1.78 PER SHARE​.VIKING THERAPEUTICS - ‍UNDER TERMS OF COMMON STOCK PURCHASE AGREEMENT, CO TO CONTROL TIMING, AMOUNT OF ANY FUTURE SALE OF SHARES OF COMMON STOCK TO LPC​.  Full Article

BRIEF-Viking Therapeutics Q4 Loss Per Share $0.14

* VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE